Health Care · Pharmaceutical Preparations

PAHC PHIBRO ANIMAL HEALTH CORP SEC Filings & Insider Trading Activity 2026

company
CIK 1069899154 filings
Russell 2000

PAHC at a glance

PHIBRO ANIMAL HEALTH CORP (PAHC, SEC CIK 1069899) filed its latest 10-K annual report on August 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), PHIBRO ANIMAL HEALTH CORP (PAHC) reported revenue of $1.5 billion (up 17.1% from FY2025) and net income of $99.7 million. Diluted EPS was $2.43.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding PHIBRO ANIMAL HEALTH CORP (PAHC) shares worth $349.4 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$1.5B
+17.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
30 funds
$349.4M · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02 · Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Business Overview

  • Core animal health and mineral nutrition business expanded via $297.5M Zoetis medicated feed additive acquisition, adding $358.2M sales in FY26
  • Launched new canine dental device, Restoris®, in Oct 2025; Rejensa® joint care supplement gained market traction in FY26
  • Strategic shift includes planned closure of Chicago Heights manufacturing facility by summer 2027 to consolidate production
  • Employee count grew to approximately 2,605 across 37 countries, up from prior years, supporting expanded global footprint
  • Regulatory challenges: navigating FDA review of carbadox residue detection, with $21M Mecadox sales at risk pending outcome

Risk Factors

  • FDA final order revoking carbadox (Mecadox) residue detection method, sales $21M FY2026; ongoing litigation to prevent loss of product approval
  • Middle East conflicts pose risk to Israeli manufacturing producing 16% of net sales; potential export disruption from regional hostilities
  • Supply chain reliant on sole source suppliers for active pharmaceutical ingredients; regulatory changes or supplier issues could interrupt product availability
  • Competition from Merck Animal Health, Zoetis, Elanco and increasing generic products pressuring pricing and market share
  • Total debt $739M (term loans $622M, revolver $116M) with restrictive covenants limiting operational flexibility and requiring significant cash flow for interest and principal payments

Management Discussion & Analysis

  • Revenue $1.52B, up 17% YoY; Animal Health $1.16B (+21%), Mineral Nutrition $282M (+11%), Performance Products $73.5M (-8%)
  • Operating margin 12.8% vs 8.5%; gross margin 33.8% vs 30.9%; net income $99.7M vs $48.3M; adjusted EBITDA margin 16.8% vs 14.2% of sales
  • Best segment Animal Health: net sales $1.16B (+$199M), adjusted EBITDA $303.6M (+$81.3M); worst segment Performance Products: net sales $73.5M (-$6.6M), adjusted EBITDA $8.1M (-$2.5M)
  • Operating cash flow $69.0M; Capex $59.1M; dividends paid $19.5M; term loan borrowings increased for $297.5M acquisition; $6.6M net cash used in financing
  • Management notes risks from Middle East conflicts affecting 16% sales/assets; regulatory headwinds on antimicrobials; expects strong demand driven by global protein consumption growth

AI summary of the PAHC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $386.8M, up 6% YoY from $363.9M, driven by Mineral Nutrition and Animal Health
  • Gross margin 33.2% vs 32.9% YoY, operating margin 12.8% vs 14.1%, net margin 7.6% vs 7.3%
  • Best segment Mineral Nutrition: revenue $73.6M, up 17%; worst Vaccines: revenue $39.5M, down 2%
  • Operating cash flow $26.1M vs $9.3M; capital expenditures $18.8M; dividends $4.9M
  • Near-term liquidity expected adequate for 12 months; Brazil virginiamycin sales fell $5.2M amid regulatory restrictions and tariff risks remain

Risk Factors

  • No material changes in risk factors from the Annual Report
  • Regulatory and compliance exposure: risks disclosed in the Annual Report remain applicable
  • Operational and market exposure: business and future results remain subject to Annual Report risks
  • Financial condition exposure: Annual Report risks could materially affect financial condition

AI summary of the PAHC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers fiscal Q1 ended September 30, 2026 operating results
  • Fiscal 2027 guidance announced for the year ending June 30, 2027

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 98.8% of voting power represented, ensuring a valid quorum for shareholder decisions
  • All three Class I nominees elected through 2029, including Daniel Bendheim, Jonathan Bendheim, and Sam Gejdenson

Item EX-99.1: Item EX-99.1

  • Q1 FY2027 sales $386.8M, up 6%, with Mineral Nutrition up 17% and Performance Products up 16%
  • Net income $29.5M, up 11%, and adjusted EPS $0.79, up 8%, despite SG&A rising 15%
Filed Nov 3, 2026Full analysis →

Item 8.01: Other Events

  • Quarterly cash dividend: $0.12 per Class A and Class B share
  • Payable December 16, 2026 to shareholders of record November 25, 2026

Item EX-99.1: Item EX-99.1

  • Quarterly cash dividend of $0.12 per Class A and Class B share
  • Payable December 16, 2026, to shareholders of record November 25, 2026
Filed Aug 26, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q4 and FY2026 operating results announced for periods ended June 30, 2026
  • FY2027 financial guidance provided for the year ending June 30, 2027

Item EX-99.1: Item EX-99.1

  • Fiscal 2026 sales $1,518.1M, up 17%, with Adjusted EBITDA $255.0M, up 39%, signaling strong post-MFA integration performance
  • Adjusted diluted EPS $3.22, up 48%, despite interest expense rising 28% to $44.4M after a $300.0M interest-rate swap expired

AI summaries of PAHC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PAHC

Don't miss the next PAHC filing

  • Alerts as it files. A push when PAHC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PAHC, by share count.
  • Ask anything. An AI agent that reads every PAHC filing and answers with sources.

PAHC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Miller Larry LeeAAug 6, 2026-
David GlennAAug 6, 2026-
Escudero Lisa AnnAAug 6, 2026-
Bendheim Daniel MAAug 6, 2026-
David GlennAAug 6, 2026-
Weinstein JudithAAug 6, 2026-
BENDHEIM JonathanAAug 6, 2026-
Rodriguez PatrickAAug 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$1.3B$1.5B
Gross Profit-$399.9M$512.5M
Operating Income$53.3M$110.5M$194.4M
Net Income$2.4M$48.3M$99.7M
Gross Margin-30.9%33.8%
Op. Margin-8.5%12.8%
Net Margin-3.7%6.6%
Balance Sheet
Total Assets-$1.4B$1.5B
Equity-$285.7M$385.5M
ROE-16.9%25.9%
Per Share
EPS$0.06$1.19$2.43
Cash Flow
Operating CF$87.6M$80.1M$69.0M

Source: XBRL data in PHIBRO ANIMAL HEALTH CORP (PAHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PAHC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PAHC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$349.4M
Q2 202630$409.3M
Q1 202631$619.4M
Q4 202528$395.5M
Q3 202528$421.4M
Q2 202528$256.4M
Q1 202524$142.8M
Q4 202420$118.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 219 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PAHC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
8-KNov 3, 2026Analysis-
4Sep 17, 2026--
4Sep 17, 2026--
8-KAug 26, 2026Analysis-
10-KAug 26, 2026Analysis
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 10, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
SC 13GJul 30, 2026-
8-KJul 28, 2026Analysis-
8-KJun 26, 2026Analysis-
4May 7, 2026-

Related Health Care companies

All Health Care →

PAHC SEC filings: frequently asked questions

Which institutions hold PAHC stock?

As of September 30, 2026, the largest PHIBRO ANIMAL HEALTH CORP (PAHC) holders among the 13F filers tracked by SignalX were BlackRock ($116.0 million), State Street Corp ($37.3 million), Vanguard Capital Management LLC ($32.9 million), Millennium Management ($29.4 million), Dimensional Fund Advisors ($19.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PAHC's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), PHIBRO ANIMAL HEALTH CORP (PAHC) reported revenue of $1.5 billion (up 17.1% from FY2025) and net income of $99.7 million. Diluted EPS was $2.43. The figures come from the XBRL data in the 10-K.

What are the main risks in PAHC's latest 10-K?

In the 10-K filed August 26, 2026, PHIBRO ANIMAL HEALTH CORP (PAHC) flagged: FDA final order revoking carbadox (Mecadox) residue detection method, sales $21M FY2026; ongoing litigation to prevent loss of product approval. Middle East conflicts pose risk to Israeli manufacturing producing 16% of net sales; potential export disruption from regional hostilities. (AI summary of the Risk Factors section.)

What did PAHC report in its latest 8-K?

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Press release covers fiscal Q1 ended September 30, 2026 operating results.

What are the latest PAHC SEC filings?

PHIBRO ANIMAL HEALTH CORP (PAHC) filed its latest 10-K annual report on August 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on September 17, 2026.

What is PAHC's SEC CIK number?

PHIBRO ANIMAL HEALTH CORP (PAHC)'s SEC Central Index Key (CIK) is 1069899. EDGAR lists every PAHC filing under that number.

Ask anything about PAHC

The research agent reads PAHC's filings, financials, insider trades and 13F holders, then answers with sources.